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Injectable bone substitutes and techniques have been developed for use in minimally invasive procedures for bone augmentation. Objective: To develop a novel injectable 
thermo-sensitive alginate hydrogel (TSAH) as a scaffold to induce bone regeneration, 
using a minimally invasive tunnelling technique. Material and Methods: An injectable 
TSAH was prepared from a copolymer solution of 8.0 wt% Poly(N-isopropylacrylamide) 
(PNIPAAm) and 8.0 wt% AAlg-g-PNIPAAm. In vitro properties of the material, such as 
its microstructure and the sustained release of recombinant human bone morphogenetic 
protein-2 (rhBMP-2), were investigated. Then, with the subperiosteal tunnelling technique, 
this material, carrying rhBMP-2, was injected under the labial periosteum of the maxillary 
anterior alveolar ridge in a rabbit model. New bone formation was evaluated by means of 
X-ray, micro-computed tomography (micro-CT), fluorescence labelling, histological study, 
and immunohistochemistry study. Results: The material exhibited good injectability and 
thermo-irreversible properties. SEM showed an interconnected porous microstructure of 
the TSAH. The result of ALP activity indicated sustained delivery of BMP-2 from the TSAH 
from days 3 to 15. In a rabbit model, both TSAH and TSAH/rhBMP-2 induced alveolar 
ridge augmentation. The percentage of mineralised tissue in the TSAH/rhBMP-2 group 
(41.6±3.79%) was significantly higher than in the TSAH group (31.3±7.21%; p<0.05). 
The density of the regenerating tissue was higher in the TSAH/rhBMP-2 group than in the 
other groups (TSAH group, positive control, blank control; p<0.05). Conclusions: The TSAH 
provided convenient handling properties for clinical application. To some extent, TSAH 
could induce ridge augmentation and mineral deposition, which can be enhanced when 
combined with rhBMP-2 for a minimally invasive tunnelling injection.
Keywords: Alveolar ridge augmentation. Minimally invasive surgical procedures. Hydrogel. 
Tissue engineering.
INTRODUCTION
Atrophic maxillary anterior alveolar ridge fails to 
provide sufficient support or aesthetics for dental 
prostheses24. Today, allografts and xenograft bone 
grafts are the major methods for augmenting 
a resorbed alveolar ridge. However, they have 
several disadvantages, such as the risk of disease 
transmission and immunological reactions3. Another 
disadvantage is that these grafts require an open 
surgical operation8. To reduce trauma and surgery 
cost, “injectable tissue-engineered bone” has 
been proposed. Injectable systems ― materials 
and techniques ― are being developed for use in 
minimally invasive procedures and their ability to 
fill irregular defects1,7.
In the late 1980s, Kent, et al.12,13 (1982, 1983) 
proposed the sub-periosteal tunnelling technique. 
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They made a small incision in the mucosa of 
the alveolar ridge, elevated the periosteal, and 
injected hydroxyapatite particles into the tunnel 
through a modified syringe. Although the material 
diffused into adjacent tissues, leading to poor bone 
regeneration, the technique attracted attention. 
However, due to the limitations of the injectable 
bone substitute material, this technique did not 
become popular clinically.
Injectable biomaterials now include synthetic 
ceramics and synthetic polymers16. In recent 
years, thermo-sensitive hydrogel systems have 
attracted much interest in the biomedical field22. 
Poly(N-isopropylacrylamide) (PNIPAAm) is one 
such synthetic polymer that can form a hydrogel 
in situ above its lower critical solution temperature 
(LCST) and maintain a liquid state below the LCST. 
Alginate is a natural polysaccharide composed 
of 1,4-linked β-D-mannuronate and 1,4-linked 
α-L-guluronate residues. It is extracted from 
algin, which is abundant and inexpensive. It 
also has the advantages of good biocompatibility 
and immunological non-responsiveness20. The 
AAlg-g-PNIPAAm copolymer, prepared through 
coupling carboxylic end-capped PNIPAAm to 
aminated alginate (AAlg), has good injectability 
and plasticity at room temperature, while it gels 
at body temperature (37°C). In particular, it has 
been shown to be non-cytotoxic and can promote 
the proliferation of entrapped cells. The degradation 
rate is controllable by changing the quantity of 
PNIPAAm23. By adding 8.0 wt% PNIPAAm to 8.0 
wt% AAlg-g-PNIPAAm copolymer, we obtained a 
TSAH that seemed to be a suitable delivery system 
for minimally invasive bone regeneration.
Bone morphogenetic protein-2 (BMP-2), one 
of the most promising osteoinductive growth 
factors, can recruit progenitor cells and promote 
the differentiation of osteoblasts2,25. Because of the 
short half-life and initial burst release of BMP-2, 
biocompatible carriers such as the thermo-sensitive 
alginate are necessary to protect its bioactivity and 
prolong the release period15.
In this study, we combined the TSAH with BMP-
2 to explore the effect of this delivery system on 
bone augmentation of the anterior alveolar ridge in 
a rabbit model, using the sub-periosteal tunnelling 
technique. The micro-structure of the TSAH and the 
sustained release properties of rhBMP-2 from the 
TSAH in vitro were also explored.
MATERIAL AND METHODS
Preparation of the TSAH
An AAlg-g-PNIPAAm copolymer with 29% 
PNIPAAm grafting was prepared. The copolymer 
was synthesised by grafting PNIPAAM-COOH 
with a single carboxyl end group onto aminated 
alginate (AAlg) through amide bond linkages23. Dry 
PNIPAAm and AAlg-g-PNIPAAm were sterilised with 
an electron beam, dissolved in phosphate buffer 
solution (PBS, pH 7.4), and stirred overnight at 
4°C. In order to obtain an optimum mixture ratio, 
different percentages of PNIPAAm (6.0, 8.0 wt%) 
were mixed into different percentages of AAlg-g-
PNIPAAm (8.0, 10.0, 12.0 wt%). We detected the 
injectability and the hardness after gelation of the 
materials at each mixture ratio. Finally, a delivery 
system containing 8.0 wt% PNIPAAm and 8.0 wt% 
AAlg-g-PNIPAAm was chosen and prepared.
Morphological observation
The TSAH was first gelled at 37°C, lyophilised 
into a dry sample, and then fractured. The cross-
section was gold-coated and the inner morphology 
of the TSAH was observed by scanning electron 
microscopy (SEM, Hitachi S-4800, Japan) at 15 kV.
Bioactivity of rhBMP-2 released from the 
hydrogel in vitro
The recombinant human BMP-2 (rhBMP-2; 
PeproTech, USA) was dissolved in PBS containing 
bovine serum albumin (BSA) (1 µg of rhBMP-2 per 
50 µg of BSA), then the solution was mixed into 
the TSAH. The final BMP-2 concentration was 50 
µg/mL. All preparations were carried out under 
aseptic conditions.
TSAH/rhBMP-2 (250 µL) and TSAH samples (250 
µL) were injected separately into 1.5-mL capped 
centrifuge tubes and incubated at 37°C for a few 
minutes for gelation. Then, 1 mL of PBS was added 
into each tube and incubated in a rotary shaker (35 
rpm) at 37°C for 21 days. At scheduled intervals 
(1, 3, 5, 7, 9, 11, 15, 18 and 21 days), 0.5 mL of 
supernatant were collected and replaced with 0.5 
mL of fresh PBS. The collected supernatant was 
sterilised by filtration and stored at -20°C for later 
use.
Human bone marrow-derived mesenchymal 
stem cells (hBMSCs) were plated at a density of 
2×104 cells per well in 24-well plates. Subsequently, 
the cells were incubated in α-MEM with 10% fetal 
bovine serum (FBS), 100 U/mL penicillin, and 100 
µg/mL streptomycin in a humidified 37°C/5% CO2 
incubator. After 24 h, the medium was replaced 
with 1 mL of fresh medium composed of obtained 
supernatant and α-MEM at a ratio of 1:7 (v/v). The 
obtained supernatant without rhBMP-2 was used 
in the negative control group while 400 ng/mL 
rhBMP-2 were used in the positive control group. 
After 5 days in culture, the medium was removed, 
the cells were washed twice with PBS, and lysed 
with 0.5 mL of 1% Triton X-100 combined with 
ultrasonication.
Alkaline phosphatase (ALP) is one of the 
most commonly used osteogenic markers. It is 
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assumed to reflect the degree of the osteogenic 
differentiation18,26. It is also well-known that BMP-2 
can increase the ALP activity of hBMSCs in a dose-
dependent manner. Thus, the amount and activity 
of BMP-2 released from the gel can be evaluated 
indirectly according to an ALP activity assay in 
vitro. The cell lysates were centrifuged and the 
supernatant was collected for ALP analysis with an 
ALP activity assay kit (Jiancheng, Nanjing, Jiangsu, 
China) according to the manufacturer’s protocol.
Animal experiments
In vivo bone augmentation
In total, sixteen male New Zealand White rabbits, 
weighing ~2.5 kg, were allowed to acclimatize for 1 
week in the laboratory animal housing prior to the 
operation. All experiment protocols were approved 
by the Biomedical Ethics Committees. Under 
general anaesthesia, through the otomarginal vein 
with pentobarbital sodium (30 mg/kg), an incision 
of ~1 mm was made in the mucoperiosteum on 
the labial side of the maxillary anterior alveolar 
bone. A subperiosteal space with dimensions of 
10×5×4 mm was created with a periosteal elevator. 
Afterwards, the material was injected through a 
syringe needle of 1.2 mm in diameter into the tunnel 
to occupy the space created and to augment the 
alveolar ridge. The incision was then closed with a 
suture (Figure 1A-D).
A total of 32 alveolar augmentation implants 
were injected bilaterally in 16 rabbits, divided 
randomly into the following four groups: A- TSAH 
(n=12, 4 for each time point: weeks 4, 8, 12); B- 
TSAH/rhBMP-2 (n=12, 4 for each time point: weeks 
4, 8, 12); C- injectable calcium phosphate/BMP-2 
as a positive control (n=4, week 12), and D- PBS 
as a blank control (n=4, week 12).
All rabbits were given antibiotics via a 
subcutaneous injection 3 days after the operation 
and were observed grossly every day. Animals were 
euthanised at 4, 8, and 12 weeks after surgery. 
Alveolar bone samples were harvested and fixed in 
10% neutral buffered formalin. All specimens were 
analysed by radiography and histologically.
Radiography analyses and micro-CT 
assessment
The gross samples were examined using a 
dental X-ray machine (Warning, Finland) at 60 
kV, 8 mA for 0.125 s. Then, they were scanned 
by micro-computed tomography (micro-CT) 
(Siemens Inveon, Germany) at 60 kV, 400 μA in 
high resolution scanning mode to determine the 
bone volume. Bone mineral density (BMD) and 
bone volume fraction (bone volume/total volume, 
BV/TV) were also determined.
Sequential fluorescent labelling
To evaluate the distribution and rate of new 
bone formation, the rabbits sacrificed at 12 weeks 
post-surgery were labelled with three polychrome 
sequential fluorescent markers. At 3, 6 and 9 
weeks after the surgical operation, the rabbits were 
injected subcutaneously at the implant sites with 
60 mg/kg tetracycline hydrochloride (TE) (Sigma, 
St Louis, MO, USA), 30 mg/kg alizarin red (AL) 
(Sigma, St Louis, MO, USA), and 10 mg/kg calcein 
(CA) (Sigma, St Louis, MO, USA), respectively.
Histological and histomorphometric 
observations
The samples harvested at 4 and 8 weeks were 
decalcified completely in 20% EDTA (pH=7.2), 
embedded in paraffin wax, and sectioned with 
a microtome (Leica RM2235, Germany) to a 
thickness of 4 μm. Then, haematoxylin and eosin 
(HE) staining was performed and the expression of 
two osteoblast differentiation markers, osteopontin 
(OPN) and osteocalcin (OCN), was examined by 
Figure 1- The subperiosteal tunnelling technique, sol-gel transformation and microstructure of the thermo-sensitive alginate 
hydrogel (TSAH). An incision was made on the mucoperiosteal surface (A), and a subperiosteal space was created (B). 
The material was injected into the tunnel to occupy the space created (C), and the incision was subsequently closed (D). 
The TSAH was flowable at room temperature (E), but gelled above the lower critical solution temperature (37°C) (F). The 
microstructure of the TSAH (G) showed an interconnected porous microstructure, like a honeycomb
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immunohistochemical staining. Those harvested 
at 12 weeks post-surgery were bisected. Half of 
the gross samples was decalcified and stained 
as above. The remaining half was dehydrated, 
embedded in polymethylmethacrylate and cut into 
150-μm-thick sections with a microtome (EXAKT 
300CP, Germany). Finally the sections were ground 
and polished to a thickness of 40 μm and observed 
under a fluorescence microscope.
Statistical analysis
All data are presented as means±standard 
deviations. Significant differences in in vitro bone 
formation analyses were analysed by one-way 
ANOVA. The differences between groups and time 
points were considered statistically significant if 
p<0.05.
RESULTS
Preparation of the TSAH
The TSAH was flowable and could be injected 
smoothly through a needle of 1.2 mm in diameter 
at room temperature. Above the LCST (37°C), it 
gelled and gained enough strength to support the 
periosteum (Figure 1E-F).
Morphological observation
The microstructure of the lyophilised TSAH was 
observed by scanning electron microscopy (SEM); 
the image is shown in Figure 1G. The hydrogel 
presented an interconnected porous microstructure, 
like a honeycomb. Interconnected pores with sizes 
in the range of 30-50 nm could be found in the 
TSAH.
Bioactivity of rhBMP-2 released from the 
hydrogel in vitro
The release profile of rhBMP-2 loaded in hydrogel 
is shown in Figure 2. ALP activity increased greatly 
at day 3, indicating that osteoblast differentiation 
was induced by the initial exposure to BMP-2, and 
then maintained until day 15. It was significantly 
higher than that in the negative control group 
(p<0.05). From day 18 to day 21, there was no 
obvious difference between the test group and 
control group. These results indicated that sustained 
delivery of BMP-2 from the gel stimulated ALP 
activity in hBMSCs from day 3 to day 15; however, 
the dose of BMP-2 released might be too low to 
affect ALP activity before and after this period.
In vivo bone formation
Radiographic examination
Radiographs were taken at 4, 8, and 12 weeks 
post-surgery for qualitative assessments of bone 
formation (Figure 3). There was no visible new 
bone formation in the samples at 4 and 8 weeks 
post-surgery in the TSAH and TSAH/rhBMP-2 
groups but augmented images above the surface 
of alveolar ridge can be seen. At 12 weeks, some 
distributed high density areas were seen within 
the material. Furthermore, the radiopaque areas 
in the TSAH/rhBMP-2 group were larger than those 
of the TSAH group. The group filled with calcium 
phosphate cement (CPC)/rhBMP-2 showed no new 
bone formation. Interestingly, high-density spots 
were distinguishable on the buccal side of the 
Figure 2- The bioactivity of the recombinant human bone morphogenetic protein-2 (rhBMP-2) released from the thermo-
sensitive alginate hydrogel (TSAH) at different time points was evaluated by the alkaline phosphatase (ALP) activity of 
human bone marrow-derived mesenchymal stem cells (hBMSCs). The blue dots represent the ALP activity of hBMSCs 
cultured in the supernatant of TSAH/rhBMP-2 of different days. The red dots represent the ALP activity of hBMSCs cultured 
in the supernatant of TSAH of different days. The dark green dot represents the ALP activity of hBMSCs cultured with 
400 ng/mL rhBMP-2 as positive control. The light green dot represents the ALP activity of hBMSCs cultured with fresh 
phosphate buffer solution (PBS) as negative control
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Figure 3- Radiographs of samples in the thermo-sensitive alginate hydrogel (TSAH) group at weeks 4, 8, and 12 (A, B, C, 
respectively), phosphate buffer solution (PBS) negative control group at week 12 (D), TSAH/bone morphogenetic protein-2 
(BMP-2) group at weeks 4, 8, and 12 (E, F, G, respectively), and the calcium phosphate cement (CPC)/BMP-2 control 
group at week 12 (H)
Figure 4- A- Representative 3D micro-computed tomography reconstruction images (A1-E1) and sectional images 
(A2-E2) of the various groups. The immediate postoperative image of the thermo-sensitive alginate hydrogel (TSAH) 
was radiolucent (A1, A2). Bone augmentation was shown in the TSAH (B1, B2) and TSAH/recombinant human bone 
morphogenetic protein-2 (rhBMP-2) groups (C1, C2) after 12 weeks, with a high-density spot in the calcium phosphate 
cement (CPC)/rhBMP-2 group (D1, D2), and no effect in the phosphate buffer solution (PBS) group (E1, E2) at 12 weeks.
B- The bone volume/total volume (BV/TV) in various groups. The thermo-sensitive alginate hydrogel/recombinant human 
bone morphogenetic protein-2 (TSAH/rhBMP-2) group had significantly more bone formation than the other groups (é 
indicates significant difference, p<0.05). C- The density of the regenerating tissue was higher in the TSAH/rhBMP-2 group 
than in the other groups (é indicates significant difference, p<0.05)
LI  Y, FANG  X, JIANG T
2015;23(2):215-23
J Appl Oral Sci. 220
alveolar ridge, 10 mm from the injecting area in 
two samples. There was no bone augmentation in 
the PBS group.
Micro-CT examination
All of the harvested samples were scanned 
and reconstructed with a micro-CT system for 
quantitative assessment of bone formation 
(Figure 4A). The images showed successful bone 
augmentation on bone surfaces in the TSAH 
groups with or without rhBMP-2. At the periphery 
of the protuberant area, the amount of new bone 
formation was higher than that in the centre. 
The analysis of regenerated bone volumes also 
indicated that alveolar ridges were augmented 
(~10×5×4 mm) in both the TSAH and the TSAH/
rhBMP-2 groups, whereas there were only high 
density spots (~1×2×2 mm) in the CPC/rhBMP-2 
group, and nothing in the PBS group at week 12. 
The percentage of mineralised tissue in the TSAH/
rhBMP-2 group (41.6±3.79%) was significantly 
higher than that in the TSAH group (31.3±7.21%; 
p<0.05; Figure 4B). The density of the regenerated 
tissue was higher in the TSAH/rhBMP-2 group than 
in the other groups (p<0.05; Figure 4C).
Sequent ia l  f luorescence label l ing 
histomorphometric analysis
The regions above the labial cortical bone 
were chosen to analyse the fluorescence labelling 
and assess the mineralisation process (Figure 
5). The results showed the shape of tetracycline 
hydrochloride (TE) labelling (yellow) matched the 
linear fibre tissue in both the TSAH and TSAH/
rhBMP-2 groups at week 3. Next, alizarin red 
(AL) labelling (red) was distributed around the TE 
labelling at week 6. Finally, calcein (CA) labelling 
(green) was detected clearly in both groups 
until week 9, indicating that mineralisation was 
occurring. There was a trend for areas of TE and AL 
labelling in the TSAH group to be weaker than those 
in the TSAH/rhBMP-2 group in the first 6 weeks. 
However, at week 9, the areas of CA labelling were 
comparable. These results demonstrated that TSAH 
alone can induce calcium deposition.
Histological evaluation
No inflammatory cells were found at 4, 8, or 12 
weeks in any group from decalcified sections stained 
with HE (Figure 6A-D). There was no evidence of 
an immune response in any group. Multinucleated 
giant cells were found adjacent to the remnant 
hydrogel, which may participate in the degradation 
of TSAH. The degradation rates of TSAH in groups 
TSAH and TSAH/rhBMP-2 increased gradually from 
weeks 4 to 12. However, at 12 weeks, some TSAH 
was not degraded and remained at the centre of 
the implantation areas. Nevertheless, some cells, 
such as osteoblasts and chondrocytes, were found 
around the remnant hydrogel at 4 weeks post-
surgery. Moreover, in some areas, osteoid structures 
were observed at 12 weeks post-surgery in the 
peripheral regions of the material in the TSAH and 
TSAH/rhBMP-2 groups. In the CPC/rhBMP-2 control 
group very little mineralised tissue was observed 
in the transplant areas at 12 weeks, consistent 
with the radiographic and micro-CT results. The 
normal anatomical structure of intact bone and the 
periosteum were seen in the PBS group.
Immunohistochemical staining of osteoblast 
differentiation markers is shown in Figures 6E-F 
(OPN) and 6G-H (OCN). Newly mineralised tissue 
showed high expression of OPN in weeks 4-12 and 
weak immunostaining for OCN in the TSAH and 
TSAH/rhBMP-2 groups.
Figure 5- Tetracycline hydrochloride (TE) labelling at 3 weeks (yellow, A1, B1), alizarin red (AL) labelling at 6 weeks (red, 
A2, B2), calcein (CA) labelling at 9 weeks (green, A3, B3), and the combination of the three types of labelling (A4, B4) in 
the various groups are shown
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DISCUSSION
Bone augmentation techniques have recently 
developed in a noticeable manner. Subperiosteal 
tunnelling injection is a minimally invasive 
technique for bone regeneration. Stevens, et al.21 
(2005) reported the use of such technique to 
obtain new bone tissue21. However, due to the poor 
plasticity of most of the injectable bone substitute 
materials10,14 and their diffusion after injection in 
vivo6, the technique has not been used widely.
The sol-gel transformation of the TSAH prepared 
here occurred at 37°C. When the flowable material 
was injected through a syringe needle into tissue, 
under the effect of body temperature, in situ it 
turned into a gel form and was stable on the bone 
surface. It was strong enough to support the 
mucoperiosteum effectively without leakage into 
the surrounding tissues like the CPC. CPC can be 
washed out by surgical bleeding after injection into 
the subperiosteum. This highlights the importance 
of choosing an appropriate protein factor carrier. 
It also showed that the TSAH material could meet 
the operating requirements.
In bone tissue engineering, the degradation rate 
of the scaffold should be consistent with the new 
Figure 6- Histological photomicrographs of various groups. Hematoxylin and eosin staining of sections in the thermo-
sensitive alginate hydrogel (TSAH) group (A), phosphate buffer solution (PBS) negative control group (B), TSAH/bone 
morphogenetic protein-2 (BMP-2) group (C) and calcium phosphate cement (CPC)/BMP-2 control group (D) at week 12 
post-surgery. The red arrows (A, C) indicate doubtful chondrocytes and osteoblasts. The blue arrow (C) indicates remnant 
hydrogel. The yellow arrow (B) indicates intact bone and periosteum. The orange arrow (D) indicates osteoid tissue. 
Osteopontin (OPN) immunohistochemical staining of sections in the TSAH (E) and TSAH/BMP-2 groups (F) at 12 weeks 
post-surgery. The red arrows indicate OPN-specific stained cells. Osteocalcin (OCN) immunohistochemical staining of 
sections in the TSAH (G) and TSAH/BMP-2 groups (H) at 12 weeks post-surgery. The red arrows indicate OCN-specific 
stained cells. The green arrow indicates dot-like OCN-specific staining
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bone formation rate17. Previous research showed 
that the degradation time of TSAH can be controlled. 
With 29% PNIPAAm grafting, 40% of the TSAH was 
degraded in 28 days, matching the bone formation 
rate23.
RhBMP-2 can effectively improve the bone 
formation and many materials have been reported 
as carriers for it in animal and clinical studies4,11. 
Alginate hydrogel can retain rhBMP-2 through an 
electrostatic interaction with the positively charged 
protein19. As a scaffold for protein growth factors, 
TSAH can provide sustained release of rhBMP-2 
and maintain its bioactivity. The rhBMP-2 released 
from the TSAH into the medium increased the ALP 
activity of hBMSCs from day 3 to day 15.
Regarding the osteogenic capabilities of TSAH 
in vivo, micro-CT showed that both the TSAH and 
TSAH/rhBMP-2 groups had high-density masses in 
the augmented area. This suggests that, with or 
without rhBMP-2, the TSAH material itself can induce 
mineralisation. When combined with rhBMP-2, the 
density and volume of mineralised tissue increased 
and osteogenesis could be enhanced.
Fluorescence labelling revealed that calcium 
deposition began at week 3 in the TSAH and 
TSAH/rhBMP-2 groups and was deposited 
continuously throughout the observation period. The 
fluorescence intensity in both groups at week 9 was 
enhanced versus that at weeks 3 and 6, suggesting 
that the mineralisation activity increased with 
time. The deposition expanded beyond the 
immediate mineralisation centre. Closer to the bone 
surface, more calcium was deposited, indicating 
that attachment to the bone surface improved 
mineralisation. In the third month, the fluorescence 
intensity increased, indicating that mineralisation 
was increasingly active. Prolonging the observation 
time may lead to detection of more bone tissue 
formation.
Osteopontin is a non-collagenous bone matrix 
glycoprotein produced by preosteoblasts and 
osteoblasts in the early stages of mesenchymal 
proliferation, pro-mineralization, and mineralization. 
It is a marker of mature osteoblasts9. Osteocalcin is 
expressed by mature osteoblasts in the late stages 
of osteogenic differentiation. It is considered the 
most specific marker of osteogenesis5. In this study, 
immunohistochemistry revealed OPN expression at 
4, 8, and 12 weeks post-surgery in both the TSAH 
and TSAH/rhBMP-2 groups, further indicating that 
the TSAH material itself can induce mineralisation 
after contact with the periosteum. There were a 
few coloured cells after OCN immunohistochemical 
staining, in which the scattered dot-like specific 
staining matched the dot-like colouring in bone 
fluorescence labelling, suggesting that calcium 
deposition activity in some areas had resulted in the 
late stage of mineralization. However, there were 
no large areas of OCN-specific staining after 12 
weeks, showing that the osteogenic differentiation 
of cells in vivo was mostly restricted to the early 
stage. From specimens at 12 weeks, alginate 
remained in the centre of the implants. Calcium 
deposition was located mainly at the edge of the 
implants. This suggests that the material needs 
further improvement. Methods could include adding 
inorganic filler to increase bone conductivity, 
enhancing nutritional metabolism inside the 
material, increasing blood supply, and adding 
further growth factor(s).
CONCLUSIONS
In this study, an injectable, sol-gel reversible 
thermo-sensitive alginate hydrogel was developed. 
With a subperiosteal tunnelling injection technique, 
this bone substitute was injected under the maxillary 
labial periosteum, gelled in situ, and finally induced 
hard tissue formation, to some extent. However, 
the hard tissue formed was mainly at the early 
stages of mineralization and predominantly at the 
periphery of the material. No mature bone tissue 
was detected. The results suggest the material 
needs further improvement.
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